Skip to main content

Clinical trial CIS-DPI-01

A Phase I/IIa First-in-Human Single-arm Open-label Multicentre Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Cisplatin-based Formulation Administered as Dry Powder for Inhalation in Combination with First Line Standard of Care in Patients with Stage IV Non-Small Cell Lung Cancer (CIS-DPI-01)

Organ Lung
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1/2a
Academic trial Non
Sponsor Inhatarget Therapeutics
EudraCT Identifier 2022-501183-17-00
Last update